Skip to main content
Top
Published in: Hepatology International 1/2024

Open Access 26-04-2023 | Hepatitis B | Original Article

Global, regional, and national burdens of cirrhosis in children and adolescents aged under 19 years from 1990 to 2019

Authors: Chi Zhang, Yiqi Liu, Hong Zhao, Guiqiang Wang

Published in: Hepatology International | Issue 1/2024

Login to get access

Abstract

Background & aims

Cirrhosis was the leading cause of morbidity and mortality in adults, but data on the burden and trends were sparse in children and adolescents. We aimed to assess the trends in 204 countries and territories over the past 30 years in children and adolescents aged 0–19 years.

Methods

Data on cirrhosis was collected by the Global Burden of Disease (GBD) 2019 database from 1990 to 2019. We reported on the number, rates, and average annual percentage changes (AAPCs) of incidence and disability-adjusted life-years (DALYs) of cirrhosis at global, regional, and national level.

Results

Globally, the incident numbers of cirrhosis in children and adolescents increased from 204,767 in 1990 to 241,364 in 2019, an increase of 17.9%, with an AAPC 0.13(0.10 to 0.16). Prevalence (AAPC = − 2.27[− 2.39 to − 2.15]), mortality (AAPC = − 1.68 [− 1.86 to − 1.5]), and DALYs rate (AAPC = − 1.72[− 1.88 to − 1.56]) of cirrhosis have decreased significantly. Cirrhosis incident rates varied between different ages. Cirrhosis caused by alcohol use (AAPC = 1[0.8 to 1.1]; incidence cases increased 48%), hepatitis C (AAPC = 0.4 [0.4 to 0.5]), NAFLD (AAPC = 0.5 [0.3 to 0.6]) have been increasing, while only hepatitis B (− 0.3[− 0.4 to − 0.2]) decreasing. Incidence cases of cirrhosis were increased in low (101.6%) and low-middle sociodemographic index (SDI 21.1%) areas, while decreasing in middle and above SDI areas. At the regional level, the largest increases count was observed in Sub-Saharan Africa.

Conclusions

Global incidence rate of cirrhosis has been increasing, while the DALYs rate has been decreasing in children and adolescents. Morbidity of cirrhosis caused by hepatitis B declined, while hepatitis C, NAFLD, and alcohol use increased.
Appendix
Available only for authorised users
Literature
4.
go back to reference Veracruz N, Gish RG, Cheung R, Chitnis AS, Wong RJ. Global trends and the impact of chronic hepatitis B and C on disability-adjusted life years. Liver Int. 2022;42(10):2145–2153CrossRefPubMed Veracruz N, Gish RG, Cheung R, Chitnis AS, Wong RJ. Global trends and the impact of chronic hepatitis B and C on disability-adjusted life years. Liver Int. 2022;42(10):2145–2153CrossRefPubMed
5.
go back to reference Population-level risks of alcohol consumption by amount. geography, age, sex, and year: a systematic analysis for the Global Burden of Disease Study 2020. Lancet (London, England). 2022;400(10347):185–235CrossRef Population-level risks of alcohol consumption by amount. geography, age, sex, and year: a systematic analysis for the Global Burden of Disease Study 2020. Lancet (London, England). 2022;400(10347):185–235CrossRef
6.
go back to reference Paik JM, Kabbara K, Eberly KE, Younossi Y, Henry L, Younossi ZM. Global burden of NAFLD and chronic liver disease among adolescents and young adults. Hepatology. 2022;75(5):1204–1217CrossRefPubMed Paik JM, Kabbara K, Eberly KE, Younossi Y, Henry L, Younossi ZM. Global burden of NAFLD and chronic liver disease among adolescents and young adults. Hepatology. 2022;75(5):1204–1217CrossRefPubMed
8.
go back to reference Armocida B, Monasta L, Sawyer S, et al. Burden of non-communicable diseases among adolescents aged 10–24 years in the EU, 1990–2019: a systematic analysis of the global burden of diseases study 2019. The Lancet Child Adoles Health. 2022;6(6):367–383CrossRef Armocida B, Monasta L, Sawyer S, et al. Burden of non-communicable diseases among adolescents aged 10–24 years in the EU, 1990–2019: a systematic analysis of the global burden of diseases study 2019. The Lancet Child Adoles Health. 2022;6(6):367–383CrossRef
9.
go back to reference Kehar M, Griffiths R, Flemming JA. Increasing incidence of cirrhosis over the past 2 decades among children in ontario. Canada Am J Gastroenterol. 2022;117(1):189–192CrossRefPubMed Kehar M, Griffiths R, Flemming JA. Increasing incidence of cirrhosis over the past 2 decades among children in ontario. Canada Am J Gastroenterol. 2022;117(1):189–192CrossRefPubMed
12.
go back to reference Schmelzer J, Dugan E, Blach S, et al. Global prevalence of hepatitis C virus in children in 2018: a modelling study. Lancet Gastroenterol Hepatol. 2020;5(4):374–392CrossRefPubMed Schmelzer J, Dugan E, Blach S, et al. Global prevalence of hepatitis C virus in children in 2018: a modelling study. Lancet Gastroenterol Hepatol. 2020;5(4):374–392CrossRefPubMed
13.
go back to reference Global age-sex-specific fertility. mortality, healthy life expectancy (HALE), and population estimates in 204 countries and territories, 1950–2019: a comprehensive demographic analysis for the global burden of disease study 2019. Lancet (London, England). 2020;396(10258):1160–1203CrossRef Global age-sex-specific fertility. mortality, healthy life expectancy (HALE), and population estimates in 204 countries and territories, 1950–2019: a comprehensive demographic analysis for the global burden of disease study 2019. Lancet (London, England). 2020;396(10258):1160–1203CrossRef
17.
go back to reference Zhang J, Ma B, Han X, Ding S, Li Y. Global, regional, and national burdens of HIV and other sexually transmitted infections in adolescents and young adults aged 10–24 years from 1990 to 2019: a trend analysis based on the global burden of disease study 2019. The Lancet Child Adolescent Health. 2022;6(11):763–776CrossRefPubMed Zhang J, Ma B, Han X, Ding S, Li Y. Global, regional, and national burdens of HIV and other sexually transmitted infections in adolescents and young adults aged 10–24 years from 1990 to 2019: a trend analysis based on the global burden of disease study 2019. The Lancet Child Adolescent Health. 2022;6(11):763–776CrossRefPubMed
18.
go back to reference Kim HJ, Fay MP, Feuer EJ, Midthune DN. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med. 2000;19(3):335–351CrossRefPubMed Kim HJ, Fay MP, Feuer EJ, Midthune DN. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med. 2000;19(3):335–351CrossRefPubMed
20.
go back to reference Li M, Su JT, Wu SS, Wei ZH, Kong YY, Jia JD. Correlation among age, sex, and liver diseases-related mortality risk in patients with hepatitis B virus-related liver cirrhosis (in Chinese). Zhonghua Gan Zang Bing Za Zhi. 2021;29(5):403–408PubMed Li M, Su JT, Wu SS, Wei ZH, Kong YY, Jia JD. Correlation among age, sex, and liver diseases-related mortality risk in patients with hepatitis B virus-related liver cirrhosis (in Chinese). Zhonghua Gan Zang Bing Za Zhi. 2021;29(5):403–408PubMed
21.
go back to reference Liu J, Liu M. Progress and challenges in achieving the WHO goal on “Elimination of Hepatitis B by 2030” in China (in Chinese). Zhonghua Liu Xing Bing Xue Za Zhi. 2019;40(6):605–609PubMed Liu J, Liu M. Progress and challenges in achieving the WHO goal on “Elimination of Hepatitis B by 2030” in China (in Chinese). Zhonghua Liu Xing Bing Xue Za Zhi. 2019;40(6):605–609PubMed
23.
go back to reference Lyu X, Liu K, Chen Y, et al. (2016) Analysis of risk factors associated with the development of hepatocellular carcinoma in chronic HBV-infected chinese: a meta-analysis. Int J Environ Res Public Health. 2016;13(6):604CrossRefPubMedPubMedCentral Lyu X, Liu K, Chen Y, et al. (2016) Analysis of risk factors associated with the development of hepatocellular carcinoma in chronic HBV-infected chinese: a meta-analysis. Int J Environ Res Public Health. 2016;13(6):604CrossRefPubMedPubMedCentral
24.
go back to reference Marcellin P, Gane E, Buti M, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet (London, England). 2013;381(9865):468–475CrossRefPubMed Marcellin P, Gane E, Buti M, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet (London, England). 2013;381(9865):468–475CrossRefPubMed
25.
go back to reference Huang DQ, El-Serag HB, Loomba R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2021;18(4):223–238CrossRefPubMed Huang DQ, El-Serag HB, Loomba R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2021;18(4):223–238CrossRefPubMed
26.
go back to reference Li J, Ha A, Rui F, et al. Meta-analysis: global prevalence, trend and forecasting of non-alcoholic fatty liver disease in children and adolescents, 2000–2021. Aliment Pharmacol Ther. 2022;56(3):396–406CrossRefPubMed Li J, Ha A, Rui F, et al. Meta-analysis: global prevalence, trend and forecasting of non-alcoholic fatty liver disease in children and adolescents, 2000–2021. Aliment Pharmacol Ther. 2022;56(3):396–406CrossRefPubMed
27.
go back to reference Younossi ZM, Otgonsuren M, Henry L, et al. Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009. Hepatology. 2015;62(6):1723–1730CrossRefPubMed Younossi ZM, Otgonsuren M, Henry L, et al. Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009. Hepatology. 2015;62(6):1723–1730CrossRefPubMed
Metadata
Title
Global, regional, and national burdens of cirrhosis in children and adolescents aged under 19 years from 1990 to 2019
Authors
Chi Zhang
Yiqi Liu
Hong Zhao
Guiqiang Wang
Publication date
26-04-2023
Publisher
Springer India
Published in
Hepatology International / Issue 1/2024
Print ISSN: 1936-0533
Electronic ISSN: 1936-0541
DOI
https://doi.org/10.1007/s12072-023-10531-y

Other articles of this Issue 1/2024

Hepatology International 1/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.